CN112852914B - Method for weakening drug resistance of tumor cells - Google Patents
Method for weakening drug resistance of tumor cells Download PDFInfo
- Publication number
- CN112852914B CN112852914B CN201911189996.4A CN201911189996A CN112852914B CN 112852914 B CN112852914 B CN 112852914B CN 201911189996 A CN201911189996 A CN 201911189996A CN 112852914 B CN112852914 B CN 112852914B
- Authority
- CN
- China
- Prior art keywords
- drug
- tumor cells
- lysine
- cells
- sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a method for separating sensitive and drug-resistant cell methylation sites by combining Stable isotope labeling technology (SILAC) with solid phase extraction-strong cation exchange resin under cell culture conditions. Culturing cells in a culture medium containing the re-marked methionine, carrying out enzymolysis by Trypsin and lysase Lys-C, carrying out enzymolysis by arginase Arg-C, carrying out SCX (soluble protein X) classification on peptide fragments of the proteolysis product, and finally carrying out LC-MS/MS analysis on the eluted peptide fragments. Different lysine and arginine methylation sites can be obtained through labelfree quantification, the methylation sites are analyzed for motif, the lysine methyltransferases of sensitive cells and drug-resistant cells have obviously different preferences, the ratio of the expression amounts of the corresponding methylation modification sites in the drug-resistant cells and the sensitive cells is obtained through comparison, and the content of the methyltransferase corresponding to the methyl site with the maximum absolute value is adjusted, so that the drug resistance of tumor cells is weakened.
Description
Technical Field
The invention belongs to the field of tumor cell drug resistance research in the proteomics research direction, and particularly relates to a method for enriching lysine and arginine methylated peptide fragments by combining a stable isotope labeling technology with solid phase extraction-strong cation exchange resin under a cell culture condition.
Background
Cancer is a common malignant tumor and a serious disease which easily causes death of human beings, and some chemotherapeutic drugs can kill cancer cells well, but can easily cause drug resistance of the cancer cells after long-term administration (document 1.Li, X.; yu, J.; brock, M.V.; tao, Q.; herman, J.G.; liang, P.; guo, M., epigenic shaping of BCL6B inactivates p53 signaling and consumers human hepatocellular resistance 2015,6, (13), 11547-11560.), so understanding the molecular mechanism of drug resistance of the cancer cells is very critical for identifying new therapeutic targets to weaken the resistance of the cells.
Intracellular signal transduction is often accomplished by different post-translational modifications of proteins, such as phosphorylation and methylation, the basic cellular transduction pathways of phosphorylation being well defined. Although methylation and phosphorylation were found to be synchronized in time, signal transduction pathways for protein methylation have not been well documented. Methylation typically occurs at arginine and lysine residues of proteins. Lysine can form monomethylation, dimethylation and trimethylation by the action of lysine methyltransferase with S-adenosylmethionine as a methyl donor (document 2.Paik, W.K., paik, D.C., kim, S.A., historial review: the field of Protein methylation.trends biochem. Sci.2007,32,146-152, document 3.lake, A.N., bedford, M.T., protein methylation and DNA repair. Mutat. Res. -Fundam.mol. Mel.2007, 618,91-101, document 4.Smith, B.C., denu, J.M., specimen of Protein methylation, biochemical engineering. Achia-Biochemical and 1745, et 2009). Arginine side chains form monomethylation and dimethylation by Arginine methyltransferase (document 5.Bedford, M.T., richard, S., arginine methyl: an empirical regulation of protein function. Molecular Cell 2005,18, 263-272), wherein dimethylation is further divided into symmetric dimethylation and asymmetric dimethylation. There is a large body of evidence that protein methylation plays a key role in maintaining intracellular function and cellular physiological and pathological changes. Histone methylation affects physical properties of chromatin, affecting gene expression (ref 6.Zhou, v.w., goren, a., bernstein, b.e., charting histones modifications and the functional organization of mammalian genes. Nature Reviews Genetics 2011,12, 7-18.). In addition to histones, methylation of lysine and arginine also occurs in non-histones and plays an important regulatory role (7. Paik, W.K., paik, D.C., kim, S., historical review: the field of protein methylation. Trends biochem. Sci.2007,32, 146-152.), however, there has been no report on how resistant methylation occurs in tumor cells.
In order to better understand the state change of protein methylation in tumor cell drug resistance, the invention is based on the combination of the re-labeled methionine mark and the solid phase extraction-strong cation exchange resin to enrich lysine and arginine methylation peptide fragments. By analyzing methylation sites motif of sensitive and drug-resistant cells, the preference of methyl transferase catalyzing the cells is obviously different, the ratio of the expression quantity of corresponding methylation modification sites in the drug-resistant and sensitive cells is obtained by comparison, and the content of the methyl transferase corresponding to the methyl site with the largest absolute value is adjusted, so that the drug resistance of tumor cells is weakened.
Disclosure of Invention
The invention aims to provide a method for enriching lysine and arginine methylation sites of sensitive and drug-resistant tumor cells, which is simple, convenient, low in cost and good in repeatability.
The method provided by the invention is characterized in that a methylated peptide fragment is separated from a complex sample by utilizing a method of culturing heavy-duty methionine and combining solid phase extraction-strong cation exchange resin, and then lysine and arginine methylation sites of the sample are obtained through mass spectrometry.
The invention adopts the following technical scheme:
cell samples cultured by re-scaling methionine are subjected to enzymolysis by Trypsin and Trypsin Lys-C, and then are subjected to enzymolysis by arginase Arg-C, and then methylated peptide fragments are separated by solid phase extraction-strong cation exchange resin, and finally the eluted peptide fragments are subjected to LC-MS/MS analysis to obtain the identification results of lysine and arginine methylation sites.
The specific steps for enriching lysine and arginine methylation sites of sensitive and drug-resistant cells are as follows:
(1) Respectively culturing sensitive and drug-resistant tumor cells in a culture medium containing re-labeled methionine for 1-10 generations, respectively dissolving the extracted proteins in a buffer solution containing 1-10M Urea and 10-100mM Tris, adding Dithiothreitol (DTT) with the final concentration of 10-100mM in a water bath at 10-100 ℃ for 1-10h, then adding Iodoacetamide (IAA) with the final concentration of 10-100mM, and carrying out a light-shielding reaction at 10-100 ℃ for 10-100min;
(2) Performing ultrafiltration centrifugation on the sample obtained after the step (1) by using an ultrafiltration tube with the molecular weight cutoff of 3-30K under the centrifugal force of 1000-20000g, adding an enzymolysis buffer solution into the trapped sample, respectively adding Trypsin and lysase with the mass ratio of 1/100-1/25 to the protein, and performing enzymolysis for 12-24h in a water bath at 37 ℃ to obtain a peptide fragment solution;
(3) Carrying out ultrafiltration centrifugation on the sample obtained after the step (2) by using an ultrafiltration tube with the molecular weight cutoff of 3-30K under the centrifugal force of 1000-20000g, adding an activation buffer solution into the trapped sample, adding arginase Arg-C with the mass ratio of the arginase Arg-C to the protein of 1/100-1/25 into the trapped sample, and carrying out enzymolysis in water bath at 37 ℃ for 12-24h to obtain a peptide fragment solution;
(4) Adding trifluoroacetic acid into the peptide fragment solution obtained in the step (3) to adjust the pH value to 2-3, then removing small molecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent;
(5) Re-dissolving 100-1000 μ g of the protein sample enzymolysis peptide fragment obtained in the step (4) in 100-1000 μ L of loading buffer solution;
(6) Adding 100-1000. Mu.L of SCX material into 1-5ml SPE column, washing 1-10 times with 100-1000. Mu.L of elution buffer, then balancing 1-10 times with 100-1000. Mu.L of loading buffer, and adding the solution obtained in the step (5) into the SPE column;
(7) Adding 100-1000. Mu.L of washing buffer solution 1 into the SPE column in the step (6), washing for 1-10 times, and collecting eluent;
(8) Adding 100-1000. Mu.L of washing buffer solution 2 into the SPE column in the step (7), washing for 1-10 times, and collecting eluent;
(9) Adding 100-1000 μ L of elution buffer solution into the SPE column in the step (8), eluting for 1-10 times, and collecting eluent;
(10) And (3) adding trifluoroacetic acid into the eluent obtained in the step (7), the step (8) and the step (9) to adjust the pH value to 2-3, then removing small molecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent.
The final concentration of the re-labeled methionine in the step (1) is 10-30mg/L.
The enzymolysis buffer solution in the step (2) is 5-100mM of tris (hydroxymethyl) aminomethane, and the pH value is 7-10 aqueous solution.
The activation buffer solution in the step (3) is 5-50mM Tris (hydroxymethyl) aminomethane with the pH value of 7-10,5-50mM dithiothreitol, 0.2-2mM EDTA and 50-500mM calcium chloride.
In the steps (5) and (6), the loading buffer solution is 1-10mM potassium dihydrogen phosphate, the pH value is 1.7-5.7, and 10-100% (V/V) acetonitrile solution.
The washing solution 1 in the step (7) is 1 to 10mM potassium dihydrogen phosphate, 10 to 100mM potassium chloride, pH 1.7 to 5.7,10 to 100% (V/V) acetonitrile in acetonitrile.
The washing solution 2 in the step (8) is an acetonitrile solution of 1 to 10mM of potassium dihydrogen phosphate, 10 to 100mM of potassium chloride, pH 1.7 to 5.7,10 to 100% (V/V) of acetonitrile.
The elution solution in step (9) is 1-10mM potassium dihydrogen phosphate, 100-1000mM potassium chloride, pH 5-10,10-100% (V/V) acetonitrile in acetonitrile.
The tumor cell is one of liver cancer, lung cancer, breast cancer, ovarian cancer and the like;
the sensitive tumor cell and the drug-resistant tumor cell are the same tumor cell;
the culture medium is required by corresponding tumor cells.
Taking tumor cells derived from tumor organisms which are administrated with the medicines to be detected as standby drug-resistant tumor cells;
taking tumor cells derived from tumor organisms which have not been taken with a medicament to be detected as standby sensitive tumor cells;
culturing standby drug-resistant tumor cells and standby sensitive tumor cells by using the drugs to be detected with the same final concentration to obtain IC50 values of the standby drug-resistant tumor cells and the standby sensitive tumor cells respectively, wherein if the ratio of the IC50 values of the standby drug-resistant tumor cells to the IC50 values of the standby sensitive tumor cells is more than or equal to 10, the standby drug-resistant tumor cells and the standby sensitive tumor cells can be used as the experimental drug-resistant tumor cells and the experimental sensitive tumor cells;
the medicine to be detected can be a medicine which can be taken by organisms with tumor diseases and can treat tumors, the medicine can be fluorouracil (5-Fu), cisplatin medicines, tamoxifen and the like, and the organisms with the tumor diseases can be white mice and white rabbits.
And (4) redissolving the lysine and arginine methylated peptide fragments obtained in the steps (7), (8) and (9) in trifluoroacetic acid with the volume concentration of 0.1% for RPLC-MS/MS analysis.
The method has the advantages of low cost, simple operation and good repeatability, and can be used for methylation proteome analysis of sensitive and drug-resistant cells.
The methylated peptide fragment enrichment material used was commercial polar MC30-SP SCX beads (Sepax).
According to the methylated peptide enrichment method, lysine and arginine methylated peptide in protein enzymatic hydrolysate are separated by strong cation exchange resin according to the ion exchange strength of the lysine and arginine methylated peptide.
The invention has the advantages that:
the enrichment method has the advantages of low cost, easy operation and good reproducibility. The invention utilizes the combination of solid phase extraction-strong cation exchange resin under the condition of culturing the re-labeled methionine for the drug resistance analysis of tumor cells and the RPLC-MS/MS analysis with high resolution, effectively enriches lysine and arginine methylation sites, can obtain different lysine and arginine methylation sites through label free quantification, finds that the lysine methyltransferases of sensitive cells and drug-resistant cells have obviously different preferences after the methylation sites are subjected to motif analysis, obtains the ratio of the expression quantity of corresponding methylation modification sites in the drug-resistant cells and the sensitive cells by comparison, and adjusts the content of the methyltransferase corresponding to the methyl site with the maximum absolute value, thereby weakening the drug resistance of the tumor cells.
Drawings
FIG. 1 is a flow chart of the method for the proteome analysis of the methylation of sensitive and resistant tumor cells. Sensitive and drug-resistant cells are cultured in a culture medium containing the re-labeled methionine, the protein of the cells is subjected to enzymolysis through a plurality of enzymes, peptide fragments after the enzymolysis are separated by solid phase extraction-strong cation exchange resin, the eluted peptide fragments are subjected to Q exact HF analysis, and then the quantitative determination is carried out by using a label free method.
FIG. 2 shows the analysis method of the methylated proteome of sensitive and drug-resistant cells, which comprises injecting DEPC water into 50 tumor-bearing mice at multiple points per week, injecting 5-Fu (3 mg/kg) into 50 tumor-bearing mice at multiple points per week, increasing 1mg/kg of drug per week for 10 weeks, and recording the volume of the tumor. ,
FIG. 3 shows the analysis method of the methylation proteome of sensitive and drug-resistant cells, tumor cells of the control group and the drug group were injected with 5-Fu at 0mg/kg, 1mg/kg, 3mg/kg, 9mg/kg and 18mg/kg of the drug, and tumor volume was recorded after one week and each concentration was repeated 3 times.
FIG. 4 is a graph of the sensitive and drug-resistant cell methylation proteome analysis method for the quantitative analysis of data in tumor cell methylation proteomics of control and drug-administered groups, wherein the results are quantitative and significantly changed methylation forms and methylated proteins.
FIG. 5 is the sensitive and drug resistant cell methylation proteomic analysis method for quantitative analysis data of tumor cell methylation proteomics of control and drug groups, (a) the motif of the lysine methylation site up-regulated, (b) the motif of the arginine methylation site up-regulated, (c) the motif of the lysine methylation site down-regulated, (d) the motif of the arginine methylation site down-regulated.
FIG. 6 is the analysis method of the methylation proteome of the sensitive and resistant cells for weakening the growth data of the tumor cells in the drug group, the tumor body of the drug group is injected with DEPC water 50 μ L at multiple points + sodium chloride injection 0.9% 200 μ L in the abdominal cavity, the tumor body is injected with DEPC water 50 μ L at multiple points + 5-Fu (3 mg/kg) in the abdominal cavity, the tumor body is injected with siRNA 500pmol + sodium chloride injection 0.9% 200 μ L in the abdominal cavity, the tumor body is injected with siRNA 500pmol + 5-Fu (3 mg/kg) at multiple points + the abdominal cavity, once per week, 4 times in total, and the tumor volume size is recorded.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
Examples
The hepatoma cell line Bel-7402 is cultured in 1640 culture medium containing 10% fetal calf serum and cultured in an incubator at 5% and 37 ℃. Preparing single cell suspension from cells in logarithmic growth phase, and adjusting the cell density to 1 \ 1093 8 One per mL. The single cell suspension was injected subcutaneously into the right back of nude mice in a dose of 200. Mu.L each with a 1mL syringe. Strictly according to aseptic operation principles. Observing the inoculation part every other day after the inoculation is finished, measuring the longest warp and the shortest warp of the tumor by using a vernier caliper, and calculating the tumor volume according to the following formula: v (mm) 3 )＝πabc/6。
When the volume of the transplanted tumor is more than 10mm 3 In the course of treatment, 100 tumor-bearing mice were randomly divided into 2 groups, namely a control group and a drug group, and each group had 50 mice. Control group: injecting DEPC water into tumor body at multiple points; the medicine group is as follows: tumor was injected with 5-Fu (3 mg/kg) at multiple injection points, 1 time per week, and 1mg/kg of drug was added per week for a total of 10 times.
Before each injection, the longest meridian a, the shortest meridian b and the height c of the tumor are measured by a vernier caliper, the tumor volume is calculated according to a formula, and the tumor volume is recorded.
Taking 15 tumor-bearing mice of a control group and 15 drug groups, injecting 5-Fu of 0mg/kg, 1mg/kg, 3mg/kg, 9mg/kg and 18mg/kg into tumor bodies of the tumor-bearing mice for one week, repeating each concentration for 3 times, calculating the tumor volume according to a formula, and calculating an IC50 value.
After determining that the tumor body of the tumor-bearing mouse has drug resistance, feeding food containing the re-labeled methionine for 2 weeks, injecting 5-Fu of 3mg/kg once a week into a drug group to maintain the drug resistance, killing the tumor-bearing mouse, taking tumor tissues, and extracting protein.
(1) Dissolving 1mg of protein of control group and drug group in buffer solution of 8M Urea and 50mM Tris, adding into 20mM DTT, water bath at 37 deg.C for 2h, then adding into 40mM IAA, and reacting at 25 deg.C in dark for 40min;
(2) Carrying out ultrafiltration centrifugation by using a 10K ultrafiltration tube at 14000g, adding 10mM of tris (hydroxymethyl) aminomethane into an intercepted sample, wherein the pH value is 8.0, then respectively adding Trypsin and lysase Lys-C with the mass ratio of 1/100 to the protein, and carrying out enzymolysis for 16h in water bath at 37 ℃ to obtain a peptide fragment solution;
(3) Carrying out ultrafiltration centrifugation by using a 10K ultrafiltration tube at 14000g, adding 5mM tris (hydroxymethyl) aminomethane with the final concentration, the pH value of 7.6,5mM dithiothreitol, 0.2mM ethylene diamine tetraacetic acid and 5mM calcium chloride buffer solution into an intercepted sample, adding arginase Arg-C with the mass ratio of 1/100 to protein into the intercepted sample, and carrying out enzymolysis for 16h in water bath at 37 ℃ to obtain a peptide fragment solution;
(4) Adding trifluoroacetic acid into the peptide fragment solution, adjusting the pH value to 2-3, removing small molecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent;
(5) Add 200. Mu.L of SCX material to a 2.5ml SPE cartridge, wash 3 times with 300. Mu.L of elution buffer (5 mM potassium dihydrogen phosphate, 500mM potassium chloride, pH 7.0,30% acetonitrile), then equilibrate 3 times with 200. Mu.L of loading buffer (5 mM potassium dihydrogen phosphate, pH 2.7,30% acetonitrile);
(6) Redissolving 1000 mug enzymolysis peptide section in 900 mul sample buffer solution, adding into SPE column;
(7) The SPE column was washed 5 times with 300. Mu.L of washing buffer 1 (5 mM potassium dihydrogen phosphate, 30mM potassium chloride, pH 2.7,30% acetonitrile) and the washings were collected;
(8) Washing SPE column with 300 μ L of washing buffer 2 (5 mM potassium dihydrogen phosphate, 40mM potassium chloride, pH 2.7,30% acetonitrile) for 3 times, and collecting the washing solution;
(9) Washing SPE column with 300 μ L of elution buffer solution for 3 times, and collecting eluate;
(10) Adding trifluoroacetic acid into the eluent to adjust the pH value to 2-3, then removing micromolecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent;
(11) The obtained lysine and arginine methylated peptide fragments were redissolved in 0.1% (v/v) trifluoroacetic acid for RP LC-MS/MS analysis.
(12) And (2) quantifying the label free of data acquired by mass spectrometry by using a Maxquant search engine, processing the quantitative result by using perseus software to obtain different methylation sites, comparing to obtain the ratio of the expression quantity of the corresponding methylation modification sites in the drug-resistant and sensitive cells, sorting the expression quantities from large to small according to the absolute value of the ratio and the 1 difference, taking lysine methyltransferases ranked at the corresponding sites in the front 1 from one end with the large absolute value for content adjustment, wherein the methylation site with the largest absolute value is a dimethylation site di-K561 of HSPA8 (the change multiple =5.12, the p value = 0.002), and the methyltransferase is METTL21A according to the literature.
(13) The siRNA technology is utilized to down-regulate METTL21A in a medicinal composition, and the specific experimental design is as follows: injecting 50 mu L of DEPC water into the tumor body at multiple points and injecting 200 mu L of 0.9 percent sodium chloride injection into the abdominal cavity; 5-Fu group: injecting DEPC water 50 mu L and intraperitoneal injection 5-Fu (3 mg/kg) into tumor body at multiple points; group of sirnas: tumor is injected with 500pmol siRNA and 200 muL sodium chloride injection of 0.9 percent in abdominal cavity in a multi-point way; siRNA in combination with 5-Fu group: tumor volume was recorded by multipoint siRNA 500pmol + intraperitoneal 5-Fu injection (3 mg/kg), once a week for a total of 4 times.
Fig. 2 is the change of the tumor volume of the tumor cells in the dosing process, and it can be seen that the tumor volume of the control group gradually increases with the increase of time, however, the tumor volume of the drug group gradually decreases with the increase of time in the initial stage, the tumor volume is minimum at the fifth week, and then the tumor volume gradually increases with the increase of time, which indicates that the drug group tumor cells have drug resistance.
FIG. 3 shows the IC50 values of tumor cells of the control group and the drug group, wherein the IC50 value of the control group is 2.069mg/kg, the IC50 value of the drug group is 61.83mg/kg, and the IC50 value of the drug group is 29.9 times of that of the control group, and the drug group can be used for the next experiment.
FIG. 4 shows the results of quantitative analysis of methylation sites, and it can be seen that a total of amounts of methylation patterns is 231, 89 are statistically significant, and 15 methylation patterns are found to be up-regulated and include 9 arginine methylation patterns and 6 lysine methylation patterns, 74 methylation patterns are down-regulated and include 42 arginine methylation patterns and 32 lysine methylation patterns, and the remaining 142 methylation patterns are unchanged, and these differential methylation patterns may play an important role in tumor cell resistance.
FIG. 5 shows the results of a motif analysis of methylation sites, from which it can be seen that the sequence characteristics of the up-regulated lysine methylated form are significantly different from those of the down-regulated methylated form, and further we have found that lysine methyltransferases in tumor cells in a drug group prefer a lysine with arginine in the ortho-methylation position, which suggests that methyltransferases of the type that prefer methylation may be associated with drug resistance in tumor cells.
FIG. 6 shows the results of the tumor cell growth volume curve, from which it can be seen that the tumor volume change trends of the control group, the 5-Fu group and the siRNA are almost consistent with the increase of time, whereas the tumor cell growth of the siRNA and 5-Fu group is obviously inhibited.
In summary, the invention relates to a method for separating methylation sites of sensitive and drug-resistant cells by combining a stable isotope labeling technology with solid phase extraction-strong cation exchange resin under a cell culture condition. The method is easy to operate, low in cost and good in reproducibility, lysine and arginine methylation sites of sensitive and drug-resistant cells can be enriched simultaneously, different lysine and arginine methylation sites can be obtained through labelfree quantification, and the content of methyltransferases corresponding to the different methylation sites is adjusted, so that the drug resistance of tumor cells is weakened.
Claims (9)
1. A method of reducing resistance to tumor cells, comprising:
respectively culturing sensitive and drug-resistant tumor cells in a culture medium containing re-labeled methionine, taking out the cultured cells to respectively extract proteins, respectively carrying out enzymolysis on the proteins by Trypsin and Lys-C, respectively carrying out enzymolysis by arginase Arg-C, respectively separating peptide fragments with positive charges by solid phase extraction on protein zymolyte according to the ionic interaction strength, wherein a filler adopted by the solid phase extraction is strong cation exchange resin, respectively obtaining a mixture of lysine and arginine methylated peptide fragments of the sensitive and drug-resistant cells, carrying out LC-MS/MS analysis, quantitatively obtaining different lysine and arginine methylated sites by label free, finding that the lysine methyltransferases of the sensitive and drug-resistant cells have obviously different preferences after carrying out motif analysis on the methylated sites, comparing the obtained ratios of the expression quantities of the corresponding methylated modified sites in the drug-resistant and sensitive cells, sorting the ratios from large to small according to the absolute values of the differences between the ratios and 1, taking the side of the corresponding modified sites which are arranged at the front 1-20 with large absolute values to adjust the content of the methyltransferases, adjusting the content of the methyltransferases which is larger than that of the lysine in the cells, and adjusting the side of the side with the needed lysine methyltransferases which is smaller than the lysine sites in the cell, and the cell which is needed to be lower than the lysine methyltransferase of the lysine in the cell side of the cell, and the cell side with the needed content of the side which is smaller than the lysine site; reducing the drug resistance of the drug-resistant cells; the tumor cell is liver cancer; the methylation site with the largest absolute value is a dimethylation site di-K561 of HSPA8, and the lysine methyltransferase is METTL21A; the specific steps for enriching lysine and arginine methylation sites of sensitive and drug-resistant cells are as follows:
(1) Respectively culturing sensitive and drug-resistant tumor cells in a culture medium containing re-labeled methionine for 1-10 generations, respectively dissolving the extracted proteins in a buffer solution containing 1-10M Urea and 10-100mM Tris, adding Dithiothreitol (DTT) with the final concentration of 10-100mM in a water bath at 10-100 ℃ for 1-10h, then adding Iodoacetamide (IAA) with the final concentration of 10-100mM, and carrying out a light-shielding reaction at 10-100 ℃ for 10-100min;
(2) Carrying out ultrafiltration centrifugation on the sample obtained after the step (1) by using an ultrafiltration tube with the molecular weight cutoff of 3-30K under the centrifugal force of 1000-20000g, adding an enzymolysis buffer solution into the trapped sample, then respectively adding Trypsin Trypsin and lysine Lys-C with the mass ratio of the Trypsin to the protein of 1/100-1/25, and carrying out enzymolysis for 12-24h in water bath at 37 ℃ to obtain a peptide fragment solution;
(3) Carrying out ultrafiltration centrifugation on the sample obtained after the step (2) by using an ultrafiltration tube with the molecular weight cutoff of 3-30K under the centrifugal force of 1000-20000g, adding an activation buffer solution into the trapped sample, adding arginase Arg-C with the mass ratio of the arginase Arg-C to the protein of 1/100-1/25 into the trapped sample, and carrying out enzymolysis in water bath at 37 ℃ for 12-24h to obtain a peptide fragment solution;
(4) Adding trifluoroacetic acid into the peptide fragment solution obtained in the step (3) to adjust the pH value to 2-3, then removing small molecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent;
(5) Re-dissolving 100-1000 μ g of the protein sample enzymolysis peptide fragment obtained in the step (4) in 100-1000 μ L of loading buffer solution;
(6) Adding 100-1000. Mu.L of SCX material into 1-5ml SPE column, washing 1-10 times with 100-1000. Mu.L of elution buffer, then balancing 1-10 times with 100-1000. Mu.L of loading buffer, and adding the solution obtained in the step (5) into the SPE column;
(7) Adding 100-1000. Mu.L of washing buffer solution 1 into the SPE column in the step (6), washing for 1-10 times, and collecting eluent;
(8) Adding 100-1000. Mu.L of washing buffer solution 2 into the SPE column in the step (7), washing for 1-10 times, and collecting eluent;
(9) Adding 100-1000 μ L of elution buffer solution into the SPE column in the step (8), eluting for 1-10 times, and collecting eluent;
(10) And (3) adding trifluoroacetic acid into the eluent obtained in the step (7), the step (8) and the step (9) to adjust the pH value to 2-3, then removing small molecules in the solution by using a C18 solid phase extraction column, and freeze-drying the obtained peptide fragment eluent.
2. The method of claim 1, wherein:
the final concentration of the re-labeled methionine in the step (1) is 10-30mg/L.
3. The method of claim 1, wherein:
the enzymolysis buffer solution in the step (2) is 5-100mM of tris (hydroxymethyl) aminomethane and the pH value is 7-10 aqueous solution.
4. The method of claim 1, wherein:
the activation buffer solution in the step (3) is 5-50mM of tris (hydroxymethyl) aminomethane, the pH value is 7-10,5-50mM of dithiothreitol, 0.2-2mM of ethylenediamine tetraacetic acid and 50-500mM of calcium chloride.
5. The method of claim 1, wherein:
the loading buffer solution in the steps (5) and (6) is 1-10mM potassium dihydrogen phosphate, the pH value is 1.7-5.7, and the acetonitrile solution of 10-100% (V/V) acetonitrile;
the washing buffer solution 1 in the step (7) is 1-10mM potassium dihydrogen phosphate, 10-100mM potassium chloride, pH value is 1.7-5.7, and acetonitrile solution of 10-100% (V/V) acetonitrile;
the washing buffer solution 2 in the step (8) is 1-10mM potassium dihydrogen phosphate, 10-100mM potassium chloride, pH value is 1.7-5.7, and acetonitrile solution of 10-100% (V/V) acetonitrile;
the elution buffer solution in the steps (6) and (9) is 1-10mM potassium dihydrogen phosphate, 100-1000mM potassium chloride and acetonitrile solution with pH value of 5-10 and 10-100% (V/V) acetonitrile.
6. The method of claim 1, wherein:
the culture medium is required by corresponding tumor cells.
7. The method of claim 1, wherein:
taking tumor cells derived from tumor organisms which are taken with a medicament to be detected as standby drug-resistant tumor cells;
taking tumor cells derived from tumor organisms which have not been taken with a medicament to be detected as standby sensitive tumor cells;
and (3) culturing the standby drug-resistant tumor cells and the standby sensitive tumor cells by using the drugs to be detected with the same final concentration to respectively obtain the IC50 values of the standby drug-resistant tumor cells and the standby sensitive tumor cells, wherein if the ratio of the IC50 values of the standby drug-resistant tumor cells to the IC50 values of the standby sensitive tumor cells is more than or equal to 10, the standby drug-resistant tumor cells and the standby sensitive tumor cells are used as the experimental drug-resistant tumor cells and the experimental sensitive tumor cells.
8. The method of claim 1, wherein:
the obtained methylated peptide containing lysine and arginine is redissolved in trifluoroacetic acid with the volume concentration of 0.01-10% for RP LC-MS/MS analysis.
9. The method of claim 1, wherein:
the lysine methyltransferase which was ranked at the corresponding site of the first 1-10 sites from the larger absolute value was taken out for content adjustment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911189996.4A CN112852914B (en) | 2019-11-28 | 2019-11-28 | Method for weakening drug resistance of tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911189996.4A CN112852914B (en) | 2019-11-28 | 2019-11-28 | Method for weakening drug resistance of tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112852914A CN112852914A (en) | 2021-05-28 |
| CN112852914B true CN112852914B (en) | 2023-01-13 |
Family
ID=75995355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911189996.4A Active CN112852914B (en) | 2019-11-28 | 2019-11-28 | Method for weakening drug resistance of tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112852914B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105277712A (en) * | 2014-07-25 | 2016-01-27 | 杭州景杰生物科技有限公司 | Method for identifying single methylated modification of lysine epsilon-amino group side chain |
| CN108072555A (en) * | 2016-11-16 | 2018-05-25 | 中国科学院大连化学物理研究所 | A kind of analysis and processing method of protein methylation and its application |
| CN108445221A (en) * | 2017-02-16 | 2018-08-24 | 中国科学院大连化学物理研究所 | A kind of identification method of protein methylation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2712747A1 (en) * | 2010-08-11 | 2012-02-11 | Universite De Montreal | Combinatory cancer treatment |
| ES2638400T3 (en) * | 2014-03-27 | 2017-10-20 | Palacky University, Olomouc | Method of predicting tumor response to DNA methylation inhibitors and alternative therapeutic regimens to overcome resistance |
-
2019
- 2019-11-28 CN CN201911189996.4A patent/CN112852914B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105277712A (en) * | 2014-07-25 | 2016-01-27 | 杭州景杰生物科技有限公司 | Method for identifying single methylated modification of lysine epsilon-amino group side chain |
| CN108072555A (en) * | 2016-11-16 | 2018-05-25 | 中国科学院大连化学物理研究所 | A kind of analysis and processing method of protein methylation and its application |
| CN108445221A (en) * | 2017-02-16 | 2018-08-24 | 中国科学院大连化学物理研究所 | A kind of identification method of protein methylation |
Non-Patent Citations (6)
Also Published As
| Publication number | Publication date |
|---|---|
| CN112852914A (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kirkwood et al. | Characterization of native protein complexes and protein isoform variation using size-fractionation-based quantitative proteomics | |
| Buccitelli et al. | mRNAs, proteins and the emerging principles of gene expression control | |
| Wang et al. | A novel quantitative mass spectrometry platform for determining protein O-GlcNAcylation dynamics | |
| Minoura et al. | Overexpression, purification, and functional analysis of recombinant human tubulin dimer | |
| US20180275040A1 (en) | Hydrogel particles with tunable optical properties and methods for using the same | |
| US11535597B2 (en) | Photoreactive ligands and uses thereof | |
| Liang et al. | SUMOylation of IQGAP1 promotes the development of colorectal cancer | |
| Morrison et al. | Proteomic analysis in the neurosciences | |
| Rogawski et al. | Characterizing endogenous protein complexes with biological mass spectrometry | |
| Kikuchi et al. | CREB is activated by ER stress and modulates the unfolded protein response by regulating the expression of IRE1α and PERK | |
| Pan et al. | Functional micropeptides encoded by long non-coding RNAs: a comprehensive review | |
| Omenn et al. | Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications | |
| Rinschen et al. | From molecules to mechanisms: functional proteomics and its application to renal tubule physiology | |
| Leng et al. | A proteomics strategy for the identification of FAT10-modified sites by mass spectrometry | |
| US11035858B2 (en) | Methods of isolating barrel-like proteases and identifying peptides processed thereby | |
| CN107794268A (en) | Detect the aptamer of people's PDL1 albumen and its prepare the application in detecting preparation | |
| Li et al. | Efficient screening of glycan-specific aptamers using a glycosylated peptide as a scaffold | |
| Pütz et al. | iTRAQ analysis of a cell culture model for malignant transformation, including comparison with 2D-PAGE and SILAC | |
| Paulo et al. | Proteome-wide protein expression profiling across five pancreatic cell lines | |
| Zhang et al. | The Insufficient Activation of RIG-I–Like Signaling Pathway Contributes to Highly Efficient Replication of Porcine Picornaviruses in IBRS-2 Cells | |
| Fedorov et al. | Mass spectrometry-based chemical proteomics for drug target discoveries | |
| Zhang et al. | Kinetics of precursor labeling in stable isotope labeling in cell cultures (SILAC) experiments | |
| CN112852914B (en) | Method for weakening drug resistance of tumor cells | |
| Zhu et al. | Global lysine crotonylation alterations of host cell proteins caused by brucella effector BspF | |
| Vargas-Diaz et al. | Automated high-throughput method for the fast, robust, and reproducible enrichment of newly synthesized proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |